HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(7- (2- (4- difluorophenyl)- 1- piperazinyl)ethyl)- 2- (2- furanyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidin- 5- amine

Also Known As:

SCH 412348; SCH-412348; SCH412348

Networked: 7 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - (7-(2-(4-difluorophenyl)-1-piperazinyl)ethyl)-2-(2-furanyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine: 7
  - Pyrimidines: 510
    - (7-(2-(4-difluorophenyl)-1-piperazinyl)ethyl)-2-(2-furanyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine: 7

Experts

1.	Hodgson, Robert A: 5 articles (04/2014 - 10/2008)
2.	Bleickardt, Carina J: 3 articles (04/2014 - 01/2012)
3.	Parker, Eric M: 3 articles (04/2014 - 10/2008)
4.	Hunter, John C: 3 articles (03/2014 - 10/2008)
5.	Varty, Geoffrey B: 2 articles (07/2009 - 10/2008)
6.	Boykow, George: 1 article (04/2014)
7.	Browne, Susan E: 1 article (04/2014)
8.	Hill, David: 1 article (04/2014)
9.	Hodge, Lisa M: 1 article (04/2014)
10.	Innocent, Nathalie: 1 article (04/2014)

Related Diseases

1.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2012 - "The present studies assessed A(2A) antagonists SCH 412348 and istradefylline in rodent prepulse inhibition (PPI), a model of psychosis. " 04/01/2014 - "SCH 412348 does not differentially disrupt PPI as do dopamine agonists, perhaps indicative of an improved psychosis profile of adenosine A(2A) antagonists, even in PD patients with decreased dopamine tone in the basal ganglia."
2.	Dyskinesias (Dyskinesia) 07/01/2009 - "These studies demonstrate that preladenant and SCH 412348 are potent and selective A(2A) receptor antagonists and provide further evidence of the potential therapeutic benefits of A(2A) receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD)." 09/01/2013 - "When delivered to animals previously sensitized with L-dopa (6 mg/kg), SCH 412348, vipadenant, caffeine or istradefylline treatment produced no dyskinesias. "
3.	Parkinson Disease (Parkinson's Disease) 04/05/2014 - "Moreover, SCH 412348 retained its efficacy in the mice as motor impairment progressed (12-22 weeks of age), demonstrating that the compound was efficacious in mild to severe Parkinson's disease-like impairment in the mice. " 04/01/2014 - "MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348."
4.	Movement Disorders (Movement Disorder) 04/05/2014 - "SCH 412348 is a potent and selective adenosine A2A receptor antagonist that shows efficacy in rodent and primate models of movement disorders. " 07/01/2009 - "Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression."
5.	Hypokinesia (Bradykinesia) 04/05/2014 - "Additionally, SCH 412348 fully restored lost functionality in a measure of hind limb bradykinesia and partially restored functionality in a rotarod test. "

Related Drugs and Biologics

1.	Dopamine Agonists (Dopamine Agonist)
2.	Dopamine (Intropin)
3.	Adenosine (Adenocard)
4.	istradefylline
5.	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amine
6.	Caffeine (No Doz)
7.	Adenosine A2A Receptor (Adenosine A2A Receptors)
8.	Levodopa (L Dopa)
9.	Amines
10.	Aripiprazole (Abilify)